Velcalcetide (AMG 416), a novel peptide agonist of the calcium-sensing receptor, reduces serum parathyroid hormone and FGF23 levels in healthy male subjects
about
FGF23 in Acute and Chronic IllnessFibroblast Growth Factor-23-A Potential Uremic ToxinLongitudinal FGF23 and Klotho axis characterization in children treated with chronic peritoneal dialysis.Clinical and Practical Use of Calcimimetics in Dialysis Patients With Secondary Hyperparathyroidism.Pharmacokinetics, Biotransformation, and Excretion of [14C]Etelcalcetide (AMG 416) Following a Single Microtracer Intravenous Dose in Patients with Chronic Kidney Disease on HemodialysisEmerging drugs for secondary hyperparathyroidism.The Use of Calcimimetics for the Treatment of Secondary Hyperparathyroidism: A 10 Year Evidence Review.Advances in pharmacotherapy for secondary hyperparathyroidism.Ways of calcium reabsorption in the kidney.Integral pharmacological management of bone mineral disorders in chronic kidney disease (part II): from treatment of phosphate imbalance to control of PTH and prevention of progression of cardiovascular calcification.Etelcalcetide: First Global Approval.Drug disposition model of radiolabeled etelcalcetide in patients with chronic kidney disease and secondary hyperparathyroidism on hemodialysis.Diseases associated with calcium-sensing receptorEtelcalcetide for the treatment of secondary hyperparathyroidism.Secondary Hyperparthyroidism: Pathogenesis, Diagnosis, Preventive and Therapeutic Strategies.Treatment of secondary hyperparathyroidism: the clinical utility of etelcalcetide.Population Pharmacokinetics and Pharmacodynamics of the Calcimimetic Etelcalcetide in Chronic Kidney Disease and Secondary Hyperparathyroidism Receiving Hemodialysis.Nonclinical Safety Profile of Etelcalcetide, a Novel Peptide Calcimimetic for the Treatment of Secondary Hyperparathyroidism.Population pharmacokinetics analysis of AMG 416, an allosteric activator of the calcium-sensing receptor, in subjects with secondary hyperparathyroidism receiving hemodialysis.Nonclinical Pharmacokinetics, Disposition, and Drug-Drug Interaction Potential of a Novel d-Amino Acid Peptide Agonist of the Calcium-Sensing Receptor AMG 416 (Etelcalcetide).A pharmacokinetic/pharmacodynamic model for AMG 416, a novel calcimimetic peptide, following a single intravenous dose in healthy subjects.Determination of Etelcalcetide Biotransformation and Hemodialysis Kinetics to Guide the Timing of Its Dosing.Formulary Drug Review: Etelcalcetide.Managing hyperparathyroidism in hemodialysis: role of etelcalcetide.Etelcalcetide, A Novel Calcimimetic, Prevents Vascular Calcification in A Rat Model of Renal Insufficiency with Secondary Hyperparathyroidism.2017 FDA Peptide Harvest
P2860
Q26778554-85D5FFBD-C0E9-49D1-A69C-57A89779AFB1Q28075648-FCE041EC-3E60-4211-A094-EB7455F4736DQ35232118-AADBFCC4-C7B5-43BB-8C9C-C201D27C9B46Q36432849-C6F3E25E-582E-4EAD-90F6-C4BCB1D40003Q37595124-E0A5E882-7687-4306-9D34-42B9E629B32AQ38363615-475CCE39-F061-4033-8D18-68EAE3AF5091Q38370743-7638B529-1C95-40F1-9A29-3C66C014F803Q38544533-961577A9-0CA5-4EDB-A95D-89B9A3FD81C2Q38786641-93B83C74-5563-4BF4-BF76-924974C0F052Q38828618-DAC2C0A4-7190-4310-B409-1F7066FA8E78Q39024226-2B1BECDF-FF47-4373-AF7F-8C9BB2ADB629Q39034625-59607176-F943-44BD-A5D6-06F5A4EEE709Q39103301-5AB7E905-8E7F-4063-9E39-7D9F0BF32FF8Q39170853-6125B474-039F-4D00-9B50-2F7EE2711A94Q39220825-ECCF903E-F811-4828-AB89-442A5EE75BEEQ39374348-02A2610E-7C64-4FAA-A227-0A7DB95D5754Q39379162-1AA68766-9C2D-416B-8772-126DB73017D8Q39949155-B20D3ADB-D2DD-4EDC-B9D7-04B92A03F15EQ41592465-7918848A-E388-4764-BCB8-39612FE81D46Q43743367-7151DA04-1136-4605-81BA-2D44C66269B4Q45755152-8FDBC1B5-F18F-4748-9468-A32C7A61D93CQ49332215-98B42AFE-B2C3-470F-8CBD-FA921F1AACFCQ49587355-6B866271-4E41-48E3-B35D-173596F688A3Q50024790-902F5C10-A08B-49C6-921E-18F4E22CD2E0Q50077724-FA3037CC-53C1-4A64-8CD6-263396DF74C2Q57179901-C1BA77C5-2F4E-456F-BCCD-5C038487992D
P2860
Velcalcetide (AMG 416), a novel peptide agonist of the calcium-sensing receptor, reduces serum parathyroid hormone and FGF23 levels in healthy male subjects
description
2013 nî lūn-bûn
@nan
2013 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Velcalcetide (AMG 416), a nove ...... evels in healthy male subjects
@ast
Velcalcetide (AMG 416), a nove ...... evels in healthy male subjects
@en
Velcalcetide (AMG 416), a nove ...... evels in healthy male subjects
@nl
type
label
Velcalcetide (AMG 416), a nove ...... evels in healthy male subjects
@ast
Velcalcetide (AMG 416), a nove ...... evels in healthy male subjects
@en
Velcalcetide (AMG 416), a nove ...... evels in healthy male subjects
@nl
prefLabel
Velcalcetide (AMG 416), a nove ...... evels in healthy male subjects
@ast
Velcalcetide (AMG 416), a nove ...... evels in healthy male subjects
@en
Velcalcetide (AMG 416), a nove ...... evels in healthy male subjects
@nl
P2093
P2860
P356
P1476
Velcalcetide (AMG 416), a nove ...... evels in healthy male subjects
@en
P2093
Andrew Vick
Gregory Bell
Karen Pickthorn
Kevin J Martin
Munro Peacock
Peter Hodsman
Saling Huang
P2860
P304
P356
10.1093/NDT/GFT417
P407
P577
2013-11-13T00:00:00Z